Department of Organ Transplantation.
Department of General Surgery.
Cir Cir. 2022;90(S1):31-37. doi: 10.24875/CIRU.21000558.
Data on hepatopancreatobiliary (HPB) surgery and COVID-19 are scarce. The objective of the study was to determine the outcomes HPB procedures during the COVID-19 pandemic and compare results to the previous year.
IRB approved study of HPB procedures (April, 2020-November, 2020). Primary endpoints: Thirty-day surgical morbidity/mortality, including COVID-19 infection. Secondary endpoints: Comparison between 2019 and 2020 procedures.
Twenty-five patients were included. In 2020, HPB procedures decreased 31.6%. About 60% developed complications (Clavien-Dindo Grade III, 20%). Three patients developed post-operative COVID-19 infection (two deaths: 66% COVID-19 mortality). When compared to the previous year, there were more emergency cases, ventilator-assisted patients (p < 0.05) and pre-operative acute renal failure (p = 0.06). Clavien-Dindo complication grades were higher in 2020. Thirty-day mortality was also higher (16% vs. 5.6%).
HPB surgical activity was negatively influenced by COVID-19 on 30-day morbidity/mortality. HPB patients who developed post-operative COVID-19 infection had a complicated course with significant mortality.
关于肝胰胆（HPB）手术和 COVID-19 的数据很少。本研究的目的是确定 COVID-19 大流行期间 HPB 手术的结果，并将其与前一年的结果进行比较。
对 HPB 手术进行了 IRB 批准的研究（2020 年 4 月至 2020 年 11 月）。主要终点：30 天手术发病率/死亡率，包括 COVID-19 感染。次要终点：2019 年与 2020 年手术的比较。
共纳入 25 例患者。2020 年，HPB 手术减少了 31.6%。约 60%的患者发生并发症（Clavien-Dindo 分级 III，20%）。3 例患者术后发生 COVID-19 感染（2 例死亡：COVID-19 死亡率为 66%）。与前一年相比，急诊病例、呼吸机辅助患者（p < 0.05）和术前急性肾功能衰竭（p = 0.06）更多。2020 年的 Clavien-Dindo 并发症分级更高。30 天死亡率也更高（16%比 5.6%）。
COVID-19 对 HPB 手术的 30 天发病率/死亡率有负面影响。术后发生 COVID-19 感染的 HPB 患者病情复杂，死亡率高。
